Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C25H27N5O5 |
Molecular Weight | 477.5124 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CC[C@H](CC#N)OC(=O)N[C@@H](C)C1=CC=CC(NC(=O)NC2=CC(OC)=C(C=C2)C3=CN=CO3)=C1
InChI
InChIKey=GYCPCOJTCINIFZ-OXJNMPFZSA-N
InChI=1S/C25H27N5O5/c1-4-20(10-11-26)35-25(32)28-16(2)17-6-5-7-18(12-17)29-24(31)30-19-8-9-21(22(13-19)33-3)23-14-27-15-34-23/h5-9,12-16,20H,4,10H2,1-3H3,(H,28,32)(H2,29,30,31)/t16-,20+/m0/s1
AVN-944 is an IMPDH (inosine 5-monophosphate dehydrogenase) inhibitor which is now being tested in phase I of clinical trials for the treatment of hematologic malignancies and solid tumors and in phase II for pancreatic cancer (in combination with gemcitabine). The drug showed good inhibition of IMPDH isoforms I and II with Ki=6-10 nM.
Originator
Sources: https://www.ncbi.nlm.nih.gov/pubmed/18712736
Curator's Comment: Licensed by Avalon Pharmaceuticals.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2002 Sources: https://www.ncbi.nlm.nih.gov/pubmed/17462731 |
|||
Target ID: CHEMBL1822 Sources: https://www.ncbi.nlm.nih.gov/pubmed/17462731 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
5418 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/18971325 |
250 mg single, oral dose: 250 mg route of administration: Oral experiment type: SINGLE co-administered: |
AVN-944 plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
14540 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/18971325 |
250 mg single, oral dose: 250 mg route of administration: Oral experiment type: SINGLE co-administered: |
AVN-944 plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
1.56 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/18971325 |
250 mg single, oral dose: 250 mg route of administration: Oral experiment type: SINGLE co-administered: |
AVN-944 plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
Sample Use Guides
Pancreatic Cancer: patients took 150, 200, 250, 300, or 400 mg q12h. Advanced Stage Solid Tumors: 150 mg twice per day escalating to 750 mg twice per day.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/17462731
CCRF-CEM, K562, and Raji cells were plated in 0.5 ml aliquots of growth medium into 48-well plates at 2×10(4) cells per well and then incubated with various concentrations of AVN-944 (1-10 uM). In cell proliferation the IC50s ranged from 0.13 to 0.16 uM for AVN-944.
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C2087
Created by
admin on Fri Dec 15 15:55:40 GMT 2023 , Edited by admin on Fri Dec 15 15:55:40 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
C49181
Created by
admin on Fri Dec 15 15:55:40 GMT 2023 , Edited by admin on Fri Dec 15 15:55:40 GMT 2023
|
PRIMARY | |||
|
I3NPL1V48Q
Created by
admin on Fri Dec 15 15:55:40 GMT 2023 , Edited by admin on Fri Dec 15 15:55:40 GMT 2023
|
PRIMARY | |||
|
9918559
Created by
admin on Fri Dec 15 15:55:40 GMT 2023 , Edited by admin on Fri Dec 15 15:55:40 GMT 2023
|
PRIMARY | |||
|
297730-17-7
Created by
admin on Fri Dec 15 15:55:40 GMT 2023 , Edited by admin on Fri Dec 15 15:55:40 GMT 2023
|
PRIMARY | |||
|
DTXSID80183921
Created by
admin on Fri Dec 15 15:55:40 GMT 2023 , Edited by admin on Fri Dec 15 15:55:40 GMT 2023
|
PRIMARY | |||
|
DB05500
Created by
admin on Fri Dec 15 15:55:40 GMT 2023 , Edited by admin on Fri Dec 15 15:55:40 GMT 2023
|
PRIMARY |
SUBSTANCE RECORD